AT:PBT Prana Biotechnology Limited

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.This company has ADRs that trade in the U.S. as the symbol ATHE.

0.05 AUD
As of 04/12/2019


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Other
Index country:  Australia
Country of incorporation:  Australia
IPO date:  01/01/1900
Stock exchange:    Asx - All Markets
Exchange country:   Australia
Market cap:   27,807,548 AUD
Current dividend yield:   0.00%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy